Navigation Links
Semafore's PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
Date:10/26/2007

SAN FRANCISCO, Oct. 26 /PRNewswire/ -- Semafore Pharmaceuticals Inc. announced today on the occasion of a poster presentation at the 2007 AACR-NCI- EORTC International Conference in San Francisco that its integrin-targeted PI3 kinase inhibitor, SF1126, showed synergistic effects with certain standard chemotherapy agents in vitro and in vivo (poster C207).

In vitro data showed significant (p<0.001) synergistic growth inhibition of prostate cancer cells with combinations of docetaxel and SF1126, as well as synergistic growth inhibition of brain cancer cells with combinations of doxorubicin and SF1126. In addition, SF1126 and rapamycin showed excellent growth inhibition synergies across all prostate, renal and non-small cell lung cancer cell lines. Simultaneous dosing of SF1126 with docetaxel in a prostate xenograft model exhibited slightly improved tumor response time versus administering SF1126 prior to docetaxel administration. In this same xenograft model, using very large tumors, it was shown that SF1126 in combination with docetaxel gave significantly greater tumor regression than did docetaxel alone (p<0.05). SF1126 as a single agent showed significant tumor growth inhibition relative to the control group (73% inhibition, p<0.01) in this model as well.

"These data support that our lead compound, SF1126, is active as a single agent and in synergy with a growing list of standard chemotherapy agents," said Edward Jacobs, Semafore's president and chief executive officer. "This provides us with a pathway to clinical development in addition to our current phase I clinical trial in patients with solid tumors. We expect to complete our phase I clinical trial in the second quarter of 2008 and then evaluate SF1126 in additional trials, both as a single and combined therapy."

About SF1126

SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class IA isoforms and other key members of the PI3K
'/>"/>

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer
5. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
6. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
9. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
10. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
11. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... CHENGDU, China , Aug. 28, 2014 /PRNewswire/ ... TPI ), a pharmaceutical company that specializes ... branded generics and active pharmaceutical ingredients (API) today ... the Company,s Qionglai Facility (QLF). ... Manufacturing Practice (GMP) dataset for China Food & ...
(Date:8/28/2014)... SALT LAKE CITY , Aug. 28, 2014 /PRNewswire-iReach/ ... in 2000 by service academy graduates, has published a ... its concentrated, three-day Leadership Excellence Course . In ... the  Leadership Excellence Course to Albuquerque , ... Tucson . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
(Date:8/28/2014)... Aug. 28, 2014 Nonin Medical, Inc., the ... noninvasive medical monitoring, today announced that the Food and ... OEM/eHealth finger pulse oximeter for use in ... plugs into a telemedicine hub or kiosk through a ... in pediatric to adult patients. The Model 3231 received ...
Breaking Medicine Technology:TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... N.J., May 03, 2007 /PRNewswire-FirstCall/ --,Alpharma ... pharmaceutical company,through its Pharmaceuticals Division, this ... study of its investigational,abuse-deterrent, extended-release opioid ... the American Pain Society in Washington, ...
... /PRNewswire-FirstCall/ --,Genelabs Technologies, Inc. announced today that ... International Conference on Antiviral,Research being held in ... virus (HCV) polymerase inhibitor,discovered by Genelabs. , ... D. Roberts,Ph.D., Director of Medicinal Chemistry at ...
Cached Medicine Technology:Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 2Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 3Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 4Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 2Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 3
(Date:8/29/2014)... August 29, 2014 RBS Reputation Management has ... Book. The service is to help those individuals and ... them on Scam Book. The service would push down the ... Scam Book complaints fully invisible on Google. , RBS ... , On being asked how company can provide guarantee of ...
(Date:8/29/2014)... August 29, 2014 A home should be a ... if unaddressed. That’s why Amica Insurance is sharing some tips to ... Council suggests taking the following safety measures: , Kitchen, ... in their original containers, and keep them away from food. ... bracket near an exit. , Bathroom , ...
(Date:8/29/2014)... has caused disease outbreaks across the Arabian Peninsula and ... has claimed the lives of several hundred people since ... have been puzzled over how easily the pathogen spreads ... led by virologists from the University of Bonn have ... the rate of human transmission is low. Still, a ...
(Date:8/29/2014)... Glendale Botox experts at Glenoaks Laser Center are ... of September. This special offer features 10 free units of ... can take advantage of this special offer to completely transform ... work with patients to determine if Botox or Juvederm is ... , Botox is a treatment made from the botulinum toxin. ...
(Date:8/29/2014)... 29, 2014 VHA Central Atlantic recognized ... in clinical care, honoring nine facilities for meeting or ... , “At Novant Health, providing quality, affordable healthcare for ... Tom Zweng, MD, executive vice president and chief medical ... a remarkable experience for each and every one of ...
Breaking Medicine News(10 mins):Health News:RBS Reputation Management Announces a New Online Reputation Management Service 2Health News:Improve Home Safety with Tips from Amica Insurance 2Health News:MERS: Low transmissibility, dangerous illness 2Health News:MERS: Low transmissibility, dangerous illness 3Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Novant Health Recognized for Excellence in Clinical Care 2Health News:Novant Health Recognized for Excellence in Clinical Care 3
... Million Required for Immediate Needs, NEW YORK, May ... China in a generation, news of its full impact ... trickling in at a,painfully slow speed., According to ... personnel by parachute from the air. The agency also ...
... obesity is a key culprit, study says , , WEDNESDAY, May ... in childhood, and that means preventive measures must be embraced ... Two of the biggest threats to heart health that trace ... official high blood pressure reading of 140/90 -- and obesity. ...
... May 14 AlphaMed Press, publisher of ... Oncologist, has,promoted George Kendall Vice President, Operations ... ), Ann Murphy, AlphaMed,s president, ... journals, Stem Cells and The Oncologist, and ...
... Charles (Charlie),Goldstein was honored with the first California ... at his home in Los Angeles,surrounded by family, ... passed away the following night. He was 87 ... The CDA Foundation Humanitarian Award was recently established ...
... Care, WASHINGTON, May 14 The nation,s leading,organization ... on Aging to look to assisted living providers for ... Richard Grimes, the CEO and President of the Assisted ... as it launched,hearings on the impact on Americans of ...
... Association (AVMA) declared a preliminary victory on several ... and pledging to,continue working toward the implementation of ... joint U.S. House of Representatives and,Senate conference committee, ... health that ranges from food safety protection and ...
Cached Medicine News:Health News:UNICEF Rushing Medical Supplies, Tents, Clean Water to Children Affected by Powerful Earthquake in China 2Health News:Heart Disease Starts Early in Life 2Health News:Heart Disease Starts Early in Life 3Health News:AlphaMed Press Names George Kendall Vice President, Operations and Business Development 2Health News:The California Dental Association Foundation Presents Inaugural Humanitarian Award to USC Mobile Dental Clinics Champion Charles M. Goldstein, DDS, MPH 2Health News:The California Dental Association Foundation Presents Inaugural Humanitarian Award to USC Mobile Dental Clinics Champion Charles M. Goldstein, DDS, MPH 3Health News:Assisted Living Industry Looks at Future of Alzheimer's 2Health News:AVMA Declares Preliminary Victory on Farm Bill Provisions 2
Inquire...
Flextend is a hydrocolloid skin barrier that is designed to be the most resistant to discharge and is the barrier of choice for urostomies and high output ileosotomies....
Premier pouches provide the ultimate in skin protection with our long wearing Flextend skin barriers and superior comfort with our soft and silky ComfortWear panels....
... APTT-based kit for the screening of factor-V-related ... of the test for the factor V:Q506 ... plasma with an excess of V-DEF Plasma ... to discriminate between heterozygous and homozygous factor ...
Medicine Products: